JP Morgan has upgraded Elanco Animal Health Inc (ELAN) to Overweight from Neutral, a decision made on October 6, 2025. The stock is currently priced at $21.93.
This upgrade underscores a more optimistic outlook on Elanco's business prospects. Analysts suggest this change may reflect improved fundamentals or enhanced confidence in the company's strategic direction. Elanco, headquartered in Greenfield, Indiana, develops, manufactures, and markets products for both pets and farm animals. The company has a diverse portfolio of approximately 200 brands, serving a global market across more than 90 countries.
Elanco's market capitalization stands at $10.6 billion, with a trailing P/E ratio of 294.25 and an EPS of $0.07. Upcoming earnings reports are scheduled for May 5, 2026, and August 5, 2026, with estimated EPS of $0.36 and $0.30, respectively. Recent earnings performance has shown surprises, notably in Q3 2025, where EPS reached $0.19 against an estimate of $0.13, indicating a 43.0% positive surprise.
As of November 1, 2025, the analyst consensus for Elanco includes 7 Strong Buy, 9 Buy, and 5 Hold ratings, suggesting a general positive sentiment towards the stock. However, it is essential for investors to consider multiple factors, including company fundamentals and industry trends, when making investment decisions. Analyst ratings can evolve over time as new information becomes available, reflecting the dynamic nature of the market.